10.6084/m9.figshare.6662468.v1
Pei Ma
Pei
Ma
Haitao Wang
Haitao
Wang
Jiangyang Sun
Jiangyang
Sun
Hongzhou Liu
Hongzhou
Liu
Chao Zheng
Chao
Zheng
Xin Zhou
Xin
Zhou
Zhongxin Lu
Zhongxin
Lu
LINC00152 promotes cell cycle progression in hepatocellular carcinoma via miR-193a/b-3p/CCND1 axis
Taylor & Francis Group
2018
Hepatocellular carcinoma
LINC00152
miR-193a/b-3p
CCND1
cell cycle
2018-06-23 10:21:44
Dataset
https://tandf.figshare.com/articles/dataset/LINC00152_promotes_cell_cycle_progression_in_hepatocellular_carcinoma_via_miR-193a_b-3p_CCND1_axis/6662468
<p>Long intergenic non-coding RNA 00152 (LINC00152) is aberrantly expressed in various human malignancies and plays an important role in the pathogenesis. Here, we found that LINC00152 is upregulated in hepatocellular carcinoma (HCC) tissues as compared to adjacent non-neoplastic tissues; gain-and-loss-of-function analyses in vitro showed that LINC00152 facilitates HCC cell cycle progression through regulating the expression of CCND1. LINC00152 knockdown inhibits tumorigenesis in vivo. MS2-RIP analysis indicated that LINC00152 binds directly to miR-193a/b-3p, as confirmed by luciferase reporter assays. Furthermore, ectopic expression of LINC00152 partially halted the decrease in CCND1 expression and cell proliferation capacity induced by miR-193a/b-3p overexpression. Thus, LINC00152 acts as a competing endogenous RNA (ceRNA) by sponging miR-193a/b-3p to modulate its target gene, CCND1. Our findings establish a ceRNA mechanism regulating cell proliferation in HCC via the LINC00152/miR-193a/b-3p/CCND1 signalling axis, and identify LINC00152 as a potential therapeutic target for HCC.</p>